BusinessKura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBy Nasdaq OMXDec 1, 2016, 12:30 PM UTC